The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations
Abstract
:1. Introduction
Aim of the Study
2. Materials and Methods
2.1. Participants
2.2. Course of the Study
2.3. Research Instruments
- The Blatt-Kupperman Index consists of 11 statements concerning the severity of menopausal symptoms (such as vasomotor symptoms, paraesthesia, insomnia, nervousness, melancholia, vertigo, fatigue, arthralgia, headache, palpitations, formication) rated by respondents on a four-point scale. The following norms were accepted: a score of 0–15, no climacteric symptoms; 15–20, slight climacteric symptoms; 20–35, moderate climacteric symptoms; and more than 35, severe climacteric symptoms [19].
- The Polish adaptation of the Women’s Health Questionnaire (WHQ) was developed by Myra Hunter in the 1980s. It serves to measure self-reported somatic and psychological symptoms faced by menopausal women. This instrument consists of 36 questions, responses to which are rated on a four-point scale. The WHQ enables a reliable assessment of nine aspects of emotional and physical health, namely, depressed mood (DEP), somatic symptoms (SOM), memory/concentration (MEM), vasomotor symptoms (VAS), anxiety/fears (ANX), sexual behavior (SEX), sleep problems (SLE), menstrual symptoms (MEN), and attractiveness (ATT). The interpretation of the raw data is based on the standards for various age brackets proposed by the author of the instrument [20].
- The Perceived Stress Scale (PSS-10) is a psychological instrument for measuring the degree to which situations in one’s life are appraised as stressful. The PSS consists of 10 questions asking about feelings and thoughts during the last four weeks. Responses are weighed on a five-point scale. The raw results are obtained through summing up individual scores after transforming them according to the key. The results converted into standardized sten norms are interpreted as follows: 1–4, low score; 5–6, average score; 7–10, high score [21].
- The State-Trait Anxiety Inventory (STAI) consists of two independent parts. The first part, STAI (X-1), measures the level of anxiety understood as the transitory and situationally conditioned status of an individual (anxiety as a state). The second part, STAI (X-2), concerns anxiety understood as a relatively permanent personality trait (anxiety as a trait). Each part includes a set of 20 statements. Respondents take a stance on each statement, choosing one of four possible answers. The scores are calculated through summing up points obtained for separate answers. Raw data are converted into standardized sten results for gender and age. The sten scale is interpreted as follows: 1–4, low levels of anxiety as a trait and as a state; 5–6, average levels of anxiety as a trait and a state; 7–10, high levels of anxiety as a trait and a state [22].
- The Beck Depression Inventory-II (BDI-II) is a 21-item self-report measure of depressive symptoms. Responses are rated on a four-point scale (0–3), then the scores are added up to give a final score. The interpretation of the results is as follows: 0–13 points, no depression or minimal depressive symptoms; 14–19 points, mild depression; 20–28 points, moderate depression; and 29–63 points, severe depression [23].
- The authors’ questionnaire consists of two versions to be used before and after prophylactic surgery, designed to collect sociodemographic and medical data and to assess the decision to undergo surgery and opinions about psychological care received before and after surgery.
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Strengths and Limitations
Author Contributions
Funding
Conflicts of Interest
Ethical Approval
Informed Consent
References
- Silver, D.P.; Livingston, D.M. Mechanism of BRCA1 tumor suppression. Cancer Discov. 2012, 2, 679–684. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Finch, A.; Evans, G.; Narod, S.A. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: Clinical management considerations and recommendations. Women’s Health (Lond.) 2000, 8, 543–555. [Google Scholar] [CrossRef] [PubMed]
- Zheng, L.; Li, S.; Boyer, G.T.; Lee, W.H. Lessons learned from BRCA1 and BRCA2. Oncogene 2000, 19, 6159–6175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abdollahian, M.; Das, T.K. A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers. Biomed. Health Inform. 2015, 19, 720–727. [Google Scholar] [CrossRef]
- Friebel, T.M.; Domchek, S.M.; Rebbeck, T.R. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: Systematic review and meta-analysis. J. Natl. Cancer Inst. 2014. [Google Scholar] [CrossRef] [Green Version]
- Whittemore, A.S.; Gong, G.; Itnyre, J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer. Am. J. Hum. Genet. 1997, 60, 496–504. [Google Scholar]
- Schrauder, M.G.; Brunel-Geuder, L.; Haberle, L.; Wunderle, M.; Hoyer, J.; Reis, A.; Schulz-Wendtland, R.; Beckmann, M.W.; Lux, M.P. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. Breast 2017, 32, 186–191. [Google Scholar] [CrossRef]
- Robson, M.E.; Boyd, J.; Borgen, P.I.; Cody, H.S. Hereditary breast cancer. Curr. Probl. Surg. 2001, 38, 387–480. [Google Scholar] [CrossRef]
- Risch, H.A.; McLaughlin, J.R.; Cole, D.E.; Rosen, B.; Bradley, L.; Fan, I.; Tang, J.; Li, S.; Zhang, S.; Shaw, P.A.; et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 2006, 98, 1694–1706. [Google Scholar] [CrossRef]
- Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117–1130. [Google Scholar] [CrossRef] [Green Version]
- Eisen, A.; Lubiński, J.; Gronwald, J.; Moller, P.; Lynch, H.T.; Klijn, J.; Kim-Sing, C.; Neuhausen, S.L.; Gilbert, L.; Ghadirian, P.; et al. Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. J. Natl. Cancer Inst. 2008, 100, 1361–1367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mavaddat, N.; Peock, S.; Frost, D.; Ellis, S.; Platte, R.; Fineberg, E.; Evans, D.G.; Lzatt, L.; Eeles, R.A.; Adlard, J.; et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Result from prospective analysis of embrace. J. Natl. Cancer Inst. 2013, 105, 812–822. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brodowska, A. Ginekologia od Teorii do Praktyki; PUM: Szczecin, Poland, 2014. [Google Scholar]
- Kwon, J.S.; Tinker, A.; Pansegrau, G.; McAlpine, J.; Housty, M.; McCullum, M.; Gilks, C.B. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet. Gynecol. 2013, 121, 14–24. [Google Scholar] [CrossRef] [PubMed]
- Finch, A.; Narod, A.S. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry BRCA mutation. A review. Maturitas 2011, 70, 261. [Google Scholar] [CrossRef]
- Felice, F.; Marchetti, C.; Boccia, S.M.; Romito, A.; Sassu, C.M.; Porpora, M.G.; Muzii, L.; Tombolini, V.; Benedetti Panici, P. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know. Cancer Treat. Rev. 2017, 61, 1–5. [Google Scholar] [CrossRef]
- Michelsen, T.M.; Dorum, A.; Dahl, A.A. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol. Oncol. 2009, 113, 128–133. [Google Scholar] [CrossRef]
- Borreani, C.; Manoukian, S.; Bianchi, E.; Brunelli, C.; Peissel, B.; Caruso, A.; Morasso, G.; Pierotti, M.A. The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers. Clin. Genet. 2014, 85, 7–15. [Google Scholar] [CrossRef]
- Kupperman, H.S.; Wetchler, B.B.; Blatt, M.H. Contemporary therapy of the menopausal syndrome. J. Am. Med. Assoc. 1959, 21, 1627–1637. [Google Scholar] [CrossRef]
- Hunter, M.S. The Women’s Health Questionnaire: A measure of mid-aged women’s perceptions of their emotional and physical health. Health Psychol. 1992, 7, 45–54. [Google Scholar] [CrossRef]
- Juczyński, Z.; Ogińska-Bulik, N. NPSR—Narzędzia Pomiaru Stresu i Radzenia Sobie ze Stresem; Zakład Poligraficzny Jerzy Engel: Warszawa, Poland, 2009. [Google Scholar]
- Wrześniewski, K.; Sosnowski, T.; Jaworowska, A.; Fecenec, D. STAI Inwentarz Stanu i Cechy Lęku Polska Adaptacja STAI—Podręcznik; Zakład Poligraficzny Jerzy Engel: Warszawa, Poland, 2011. [Google Scholar]
- Beck, A.T.; Steet, R.A.; Ball, R.; Ranieri, W.F. Comparison of Beck Depression Inventories-IA and II in Psychiatric Outpatients. J. Personal. Assess. 1996, 67, 588–597. [Google Scholar] [CrossRef]
- Fritz, C.O.; Morris, P.E.; Richler, J.J. Effect size estimates: Current use, calculations and interpretation. J. Exp. Psychol. Gen. 2012, 141, 2. [Google Scholar] [CrossRef] [Green Version]
- Cohen, J. Statistical Power Analysis for the Behavioral Sciences; Erlbaum: Hillsdale, NJ, USA, 1988. [Google Scholar]
- Corder, G.W.; Foreman, D.I. Nonparametric statistics: A Step-by-Step Approach; John Wiley & Sons: Hoboken, NJ, USA, 2014. [Google Scholar]
- Moscucci, O.; Clarke, A. Prophylactic oophorectomy: A historical perspective. J. Epidemiol. Community Health 2007, 61, 182–184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rebbeck, T.R.; Lynch, H.T.; Neuhausen, S.L.; Narod, S.A.; Van’t Veer, L.; Garber, J.E.; Evans, G.; Isaacs, C.; Daly, M.B.; Matloff, E.; et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 2002, 346, 1616–1622. [Google Scholar] [CrossRef] [PubMed]
- The American College of Obstetricians and Gynecologist; ACOG Committee on Practice Bulletins—Gynecology; ACOG Committee of Genetics; Society of Gynecologic Oncologist. ACOG practice bulletin no. 103: Hereditary breast and ovarian cancer syndrome. Obstet. Gynecol. 2009, 113, 957–966. [Google Scholar] [CrossRef] [PubMed]
- Chudecka-Głaz, A.; Cymbaluk-Płoska, A.; Strojna, A.; Menkiszak, J. HE4 serum levels in patients with BRCA1 gene mutation undergoing prophylactic surgery as well as in other benign and malignant gynecological diseases. Dis. Markers 2017, 1, 1–13. [Google Scholar] [CrossRef]
- Lee, Y.C.; Bressel, M.; Grant, P.; Russel, P.; Smith, C.; Picken, S.; Camm, S.; Kiely, B.E.; Milne, R.L.; McLachlan, S.A.; et al. Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer. Fam. Cancer 2017. [Google Scholar] [CrossRef] [Green Version]
- Sherman, M.E.; Piedmonte, M.; Mai, P.L.; Ioffe, O.B.; Ronnett, B.M.; Van, L.L.; Ivanov, I.; Bell, M.C.; Blank, S.V.; DiSilvestro, P.; et al. Pathologic findings at risk-reducing salpingo-oophorectomy: Primary results from Gynecologic Oncology Group Trial GOG-0199. J. Clin. Oncol. 2014, 32, 3275–3283. [Google Scholar] [CrossRef]
- Fry, A.; Busby-Earle, C.; Rush, R.; Cull, A. Prophylactic oophorectomy versus screening: Psychosocial outcomes in women at increased risk of ovarian cancer. Psycho Oncol. 2001, 10, 231–241. [Google Scholar] [CrossRef]
- Elit, L.; Esplen, M.J.; Butler, K.; Narod, S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam. Cancer 2001, 1, 149–156. [Google Scholar] [CrossRef]
- Robson, M.; Hensley, M.; Barakat, R.; Brown, C.; Chi, D.; Poynor, E.; Offit, K. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol. Oncol. 2003, 89, 281–287. [Google Scholar] [CrossRef]
- Madalinska, J.B.; van Beurden, M.; Bleiker, E.M.; Valdimarsdottir, H.B.; Hollenstein, J.; Massuger, L.F.; Gaarenstroom, K.N.; Mourits, M.J.; Verheijen, R.H.; van Dorsr, E.B.; et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J. Clin. Oncol. 2006, 24, 3576–3582. [Google Scholar] [CrossRef] [PubMed]
- Finch, A.; Metcalfe, K.A.; Chiang, J.; Elit, L.; McLaughlin, J.; Springate, C. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psycho Oncol. 2013, 22, 212–219. [Google Scholar] [CrossRef] [PubMed]
- Johansen, N.; Liavaag, A.H.; Tanbo, T.G.; Dahl, A.A.; Pripp, A.H.; Michelsen, T. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecol. Oncol. 2016, 140, 101–106. [Google Scholar] [CrossRef] [PubMed]
- Fakkert, I.; Abma, E.; Westrik, I.; Lefrandt, J.; Wolffenbuttel, B.; Oosterwijk, J. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk of breast and ovarian cancer. Eur. J. Cancer 2015, 51, 400–408. [Google Scholar] [CrossRef] [Green Version]
- Claes, E.; Evers-Kiebooms, G.; Denayer, L.; Decruyenaere, M.; Boogaerts, A.; Philippe, K.; Legius, E. Predictive genetic testing for hereditary breast and ovarian cancer: Psychological distress and illness representations 1 year following disclosure. J. Genet. Couns. 2005, 14, 349–363. [Google Scholar] [CrossRef]
- Joffe, H.; Petrillo, L.F.; Koukopoulos, A.; Viguera, A.C.; Hirchberg, A.; Nonacs, R.; Somley, B.; Pasciullo, E.; White, D.P.; Hall, J.E.; et al. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J. Clin. Endocrinol. Metab. 2011, 96, E1044–E1054. [Google Scholar] [CrossRef]
- Fang, C.Y.; Cherry, C.; Devarajan, K.; Li, T.; Malick, J.; Daly, M.B. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol. Oncol. 2009, 112, 594–600. [Google Scholar] [CrossRef] [Green Version]
- Tucker, P.E.; Bulsara, M.K.; Salfinger, S.G.; Jit-Sun Tan, J.; Green, H.; Cohen, P.A. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol. Oncol. 2016, 140, 95–100. [Google Scholar] [CrossRef]
- Lorenz, T.; McGregor, B.; Swisher, E. Relationship satisfaction predicts sexual activity following risk-reducing salpingo-oophorectomy. J. Psychosom. Obstet. Gynaecol. 2014, 35, 62–68. [Google Scholar] [CrossRef] [Green Version]
- Bonadies, D.C.; Moyer, A.; Matloff, E.T. What I wish I’d known before surgery: BRCA carriers perspective after bilateral salpingo-oophorectomy. Fam. Cancer 2011, 10, 79–85. [Google Scholar] [CrossRef]
- Bove, R.; Secor, E.; Chibnik, L.B.; Barnes, L.L.; Schneider, J.A.; Bennett, D.A.; De Jager, P.L. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014, 82, 222–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zeydan, B.; Tosakulwong, N.; Schwarz, C.G.; Senjem, M.L.; Gunter, J.L.; Reid, R.I.; Gazzuola Rocca, L.; Lesnick, T.G.; Smith, C.Y.; Bailey, K.R.; et al. Association of Bilateral Salpingo-Oophorectomy before menopause onset with medial temporal lobe neurodegeneration. JAMA Neurol. 2018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shigehiro, M.; Kita, M.; Takeuchi, S.; Ashihara, Y.; Arai, M.; Okamura, H. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: A preliminary report. Jpn. J. Clin. Oncol. 2016, 46, 254–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bromberger, J.T.; Epperson, C.N. Depression during and after perimenopause: Impact of hormones, genetics and environmental determinants of disease. Obstet. Gynecol. Clin. N. Am. 2018, 45, 663–678. [Google Scholar] [CrossRef] [PubMed]
QoL Domain | before RRSO | after RRSO | t | p * | Effect Size ** | ||||
---|---|---|---|---|---|---|---|---|---|
M ± SD | Min–Max | CV [%] | M ± SD | Min–Max | CV [%] | ||||
Depressed mood (DEP) | 0.80 ± 0.26 | 0.14–1 | 32.2 | 0.77 ± 0.26 | 0.14–1 | 33.3 | 1.671 | 0.100 | - |
Somatic symptoms (SOM) | 0.70 ± 0.25 | 0.14–1 | 35.9 | 0.61 ± 0.25 | 0.14–1 | 40.0 | 3.925 | 0.000 | 0.360 |
Memory/concentration (MEM) | 0.70 ± 0.36 | 0–1 | 50.5 | 0.64 ± 0.36 | 0–1 | 56.6 | 2.168 | 0.034 | 0.167 |
Vasomotor symptoms (VAS) | 0.66 ± 0.43 | 0–1 | 64.1 | 0.25 ± 0.32 | 0–1 | 127.6 | 7.743 | 0.000 | 0.953 |
Anxiety/fears (ANX) | 0.82 ± 0.23 | 0.25–1 | 27.9 | 0.79 ± 0.26 | 0–1 | 32.3 | 1.803 | 0.076 | - |
Sexual behavior (SEX) | 0.58 ± 0.36 | 0–1 | 61.4 | 0.48 ± 0.36 | 0–1 | 74.6 | 3.751 | 0.000 | 0.278 |
Sleep problems (SLE) | 0.71 ± 0.32 | 0–1 | 45.8 | 0.59 ± 0.35 | 0–1 | 59.2 | 3.944 | 0.000 | 0.375 |
Menstrual symptoms (MEN) | 0.78 ± 0.24 | 0.25–1 | 31.4 | 0.79 ± 0.24 | 0–1 | 30.8 | −0.574 | 0.568 | - |
Attractiveness (ATT) | 0.59 ± 0.35 | 0–1 | 58.9 | 0.60 ± 0.34 | 0–1 | 56.7 | −0.299 | 0.766 | - |
Parameters of Psychosocial Functioning | before RRSO | after RRSO | t | p * | Effect Size ** | ||||
---|---|---|---|---|---|---|---|---|---|
M ± SD | Min–Max | CV [%] | M ± SD | Min–Max | CV [%] | ||||
Anxiety as a state (STAI X-1) | 5.9 ± 2.10 | 1–10 | 35.3 | 5.1 ± 1.73 | 1–9 | 33.9 | 4.273 | 0.000 | 0.381 |
Anxiety as a trait (STAI X-2) | 4.4 ± 2.20 | 1–10 | 49.6 | - | - | - | - | - | - |
Climacteric symptoms as determined by the Blatt-Kupperman Index | 28.7 ± 24.16 | 0–104 | 84.1 | 36.3 ± 22.10 | 4–108 | 60.9 | −6.561 | 0.000 | 0.315 |
Stress as determined by the PSS-10 | 5.5 ± 1.91 | 2–9 | 34.6 | 5.7 ± 1.85 | 2–10 | 32.7 | −0.782 | 0.437 | - |
Depressive symptoms as determined by the BDI | 8.2 ± 8.8 | 0–43 | 107.8 | 9.3 ± 8.70 | 0–43 | 93.1 | −2.471 | 0.016 | 0.125 |
Level of Anxiety as a State According to STAI X-1 | rho | p | rho | p |
---|---|---|---|---|
before RRSO | after RRSO | |||
Depressed mood (DEP) | −0.61 | 0.000 | −0.43 | 0.000 |
Somatic symptoms (SOM) | −0.45 | 0.000 | −0.18 | 0.165 |
Memory/concentration (MEM) | −0.43 | 0.001 | −0.18 | 0.156 |
Vasomotor symptoms (VAS) | −0.06 | 0.668 | 0.01 | 0.959 |
Anxiety/fears (ANX) | −0.60 | 0.000 | −0.36 | 0.004 |
Sexual behavior (SEX) | −0.30 | 0.020 | −0.01 | 0.938 |
Sleep problems (SLE) | −0.45 | 0.000 | −0.33 | 0.009 |
Menstrual symptoms (MEN) | −0.19 | 0.151 | −0.15 | 0.247 |
Attractiveness (ATT) | −0.49 | 0.000 | −0.38 | 0.003 |
The Level of Anxiety as a Trait as Determined by STAI X-2 | rho | p | rho | p |
---|---|---|---|---|
before RRSO | after RRSO | |||
Depressed mood (DEP) | −0.54 | 0.000 | −0.49 | 0.000 |
Somatic symptoms (SOM) | −0.36 | 0.004 | −0.32 | 0.013 |
Memory/concentration (MEM) | −0.43 | 0.001 | −0.39 | 0.002 |
Vasomotor symptoms (VAS) | 0.09 | 0.483 | −0.10 | 0.435 |
Anxiety/fears (ANX) | −0.53 | 0.000 | −0.46 | 0.000 |
Sexual behavior (SEX) | −0.30 | 0.020 | −0.23 | 0.071 |
Sleep problems (SLE) | −0.41 | 0.001 | −0.47 | 0.000 |
Menstrual symptoms (MEN) | −0.30 | 0.021 | −0.18 | 0.171 |
Attractiveness (ATT) | −0.50 | 0.000 | −0.37 | 0.003 |
Level of Stress as Determined by the PSS-10 | rho | p | rho | p |
---|---|---|---|---|
before RRSO | after RRSO | |||
Depressed mood (DEP) | −0.68 | 0.000 | −0.67 | 0.000 |
Somatic symptoms (SOM) | −0.39 | 0.002 | −0.36 | 0.005 |
Memory/concentration (MEM) | −0.57 | 0.000 | −0.44 | 0.000 |
Vasomotor symptoms (VAS) | 0.06 | 0.669 | 0.00 | 0.986 |
Anxiety/fears (ANX) | −0.60 | 0.000 | −0.47 | 0.000 |
Sexual behavior (SEX) | −0.34 | 0.008 | −0.26 | 0.045 |
Sleep problems (SLE) | −0.49 | 0.000 | −0.46 | 0.000 |
Menstrual symptoms (MEN) | −0.35 | 0.005 | −0.41 | 0.001 |
Attractiveness (ATT) | −0.46 | 0.000 | −0.36 | 0.005 |
Severity of Depressive Symptoms as Determined by the BDI | rho | p | rho | p |
---|---|---|---|---|
before RRSO | after RRSO | |||
Depressed mood (DEP) | −0.69 | 0.000 | −0.72 | 0.000 |
Somatic symptoms (SOM) | −0.47 | 0.000 | −0.32 | 0.013 |
Memory/concentration (MEM) | −0.60 | 0.000 | −0.52 | 0.000 |
Vasomotor symptoms (VAS) | −0.16 | 0.216 | −0.18 | 0.171 |
Anxiety/fears (ANX) | −0.63 | 0.000 | −0.56 | 0.000 |
Sexual behavior (SEX) | −0.40 | 0.001 | −0.33 | 0.010 |
Sleep problems (SLE) | −0.54 | 0.000 | −0.56 | 0.000 |
Menstrual symptoms (MEN) | −0.35 | 0.005 | −0.22 | 0.096 |
Attractiveness (ATT) | −0.59 | 0.000 | −0.36 | 0.004 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Stanisz, M.; Panczyk, M.; Kurzawa, R.; Grochans, E. The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations. Int. J. Environ. Res. Public Health 2019, 16, 4995. https://doi.org/10.3390/ijerph16244995
Stanisz M, Panczyk M, Kurzawa R, Grochans E. The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations. International Journal of Environmental Research and Public Health. 2019; 16(24):4995. https://doi.org/10.3390/ijerph16244995
Chicago/Turabian StyleStanisz, Marta, Mariusz Panczyk, Rafał Kurzawa, and Elżbieta Grochans. 2019. "The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations" International Journal of Environmental Research and Public Health 16, no. 24: 4995. https://doi.org/10.3390/ijerph16244995
APA StyleStanisz, M., Panczyk, M., Kurzawa, R., & Grochans, E. (2019). The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations. International Journal of Environmental Research and Public Health, 16(24), 4995. https://doi.org/10.3390/ijerph16244995